WEDNESDAY, Jan. 11 (HealthDay News) -- A new type of stem cell
treatment for people with type 1 diabetes appears to help
re-educate rogue immune system cells, which allows cells in the
pancreas to start producing insulin again.
The treatment, which combines a patient's immune system cells
with stem cells from a donor's cord blood, even worked in people
with long-standing diabetes who were believed to have no
Although the treatment didn't wean anyone off insulin
completely, average blood sugar levels dropped significantly, which
would reduce the risk of long-term complications.
"Our study brings a new hope for people with type 1 diabetes. If we can control the autoimmunity, we may reverse the diabetes. We showed that the islets [cells] can start to work again," said Dr. Yong Zhao, an assistant professor in the section of endocrinology, diabetes and metabolism at the University of Illinois at Chicago.
This treatment could potentially be useful in other autoimmune
diseases, such as lupus and rheumatoid arthritis.
"It's quite remarkable that this approach, based on the re-education of immune cells, might work so well. The concept is very intriguing, and the treatment seems to be so simple and so safe," said Dr. Luca Inverardi, deputy director of translational research at the Diabetes Research Institute, University of Miami School of Medicine.
But he's also "reasonably cautious," he said. "The follow-up is
long, up to 40 weeks, but it's not long enough to declare victory
against diabetes yet," said Inverardi.
Also, he noted that the study involved only 15 Chinese people,
and that type 1 diabetes is a bit different in that population. He
said he'd like to see larger studies with a more diverse
population, followed for a longer time.
Results of the study were published online Jan. 9 in the journal
Type 1 diabetes, an autoimmune disease, occurs when the body's
immune system cells mistakenly attack the insulin-producing (beta)
cells in the pancreas. Because their beta cells don't produce
enough or any insulin, people with type 1 diabetes have to replace
the lost insulin through injections to survive.
Stopping that autoimmune attack appears to be crucial to any
treatment that hopes to cure or reverse type 1 diabetes.
Zhao's team developed a completely new approach. They take blood
from a patient and separate out the immune system cells
(lymphocytes). They briefly expose those cells to stem cells from
umbilical cord blood from an unrelated infant and return the
lymphocytes alone to the patient's body. The researchers have
dubbed this "Stem Cell Educator Therapy," because while exposed to
the stem cells, the lymphocytes seem to relearn how they should
The study participants, who were 15 to 41 years old, had had
type 1 diabetes for an average of nine years. Six had some residual
beta cell function and six did not. Both groups were given stem
cell educator therapy. The other three people served as the control
The researchers measured C-peptide, a protein fragment that's a
byproduct of insulin production, and found that the educator
therapy group had improved levels of C-peptide at 12 weeks. These
levels continued to improve until 24 weeks, and remained stable
through the follow-up at 40 weeks. There were no changes in
C-peptide in the control group.
The average daily dose of insulin dropped almost 39 percent
after 12 weeks for the group with some beta cell function and 25
percent in those with no beta cell function, suggesting that the
group with no beta cell function now produced insulin.
"That means if you stop the autoimmune reaction, you may see beta cell regeneration, or there might be other precursor cells in the pancreas. If these data are confirmed, this is a very provocative and remarkable finding," Inverardi said.
The average hemoglobin A1C level dropped 1.06 percent for those
with residual beta cell function and 1.68 percent for those without
beta cell function. A1C levels measure average blood sugar levels
over two to three months, and people with type 1 diabetes are
advised to maintain A1C levels below 7 percent. A drop of 1 percent
in A1C levels can reduce the risk of complications.
This was an initial clinical trial designed to test for safety.
Zhao said that in future trials he hopes that with additional
treatments people might get off insulin altogether.
But, even if that's not possible, the recovery of some beta cell
function would be welcome news. "In the absence of complete
remission, there are very sizable advantages to having some beta
cell function," Inverardi noted.
Both experts said the treatment appears safe, with no risk of
rejection. No significant side effects were reported during the
trial, other than some arm soreness where blood was taken and
Learn more about type 1 diabetes from the
Nemours Foundation's KidsHealth Web site.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.